Cargando…
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
BACKGROUND: The molecular characteristics associated with the response to treatment in glioblastomas (GBMs) remain largely unknown. We performed a retrospective study to assess the genomic characteristics associated with the response of GBMs to either first-line chemotherapy or radiation therapy. Th...
Autores principales: | Ducray, François, de Reyniès, Aurélien, Chinot, Olivier, Idbaih, Ahmed, Figarella-Branger, Dominique, Colin, Carole, Karayan-Tapon, Lucie, Chneiweiss, Hervé, Wager, Michel, Vallette, François, Marie, Yannick, Rickman, David, Thomas, Emilie, Delattre, Jean-Yves, Honnorat, Jérôme, Sanson, Marc, Berger, François |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944185/ https://www.ncbi.nlm.nih.gov/pubmed/20822523 http://dx.doi.org/10.1186/1476-4598-9-234 |
Ejemplares similares
-
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
por: Laffaire, Julien, et al.
Publicado: (2014) -
A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA)
por: Laigle-Donadey, Florence, et al.
Publicado: (2019) -
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
por: Kamoun, Aurélie, et al.
Publicado: (2016) -
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
por: Ducray, François, et al.
Publicado: (2008) -
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)